GERMANTOWN, Wis. and
WILMINGTON, N.C., Oct. 29, 2013 /PRNewswire/ -- Cambridge
Major Laboratories, Inc. ("CML"), a global leader in pharmaceutical
API development and manufacturing, and AAIPharma Services, Corp.
("AAIPharma"), a leading global provider of pharmaceutical
analytical testing, product development and manufacturing services,
announce the appointment of Patrick D. Walsh as the Chief Executive
Officer (CEO) of the merged company.
(Logo:
http://photos.prnewswire.com/prnh/20131029/CG06001LOGO)
Kyle Bradford, American Capital
Managing Director, said, "We are very excited to be working with
Pat on the continued growth of CML and AAIPharma. He is a
well-respected CEO with over 30 years of leadership experience in
the pharmaceutical industry. AAIPharma's industry-leading
formulation development and analytical service offerings complement
CML's world-class API development and manufacturing capabilities,
and the combination creates an industry-leading contract
development and manufacturing organization ("CDMO") that is
positioned for significant growth and expansion." "The client
response to our merger announcement has been very positive," said
Mr. Walsh. "Providing an integrated service offering, coupled
with a stellar regulatory track record, allows the combined
business to exceed the expectations of our global pharma client
base."
The combined company forms the premier global supplier of
integrated CMC services, including process chemistry, solid state
chemistry, API manufacturing, formulation development, analytical
development and testing services, clinical and commercial finished
dosage form manufacturing (oral solid and sterile), packaging and
stability services.
The merger was announced by Water Street Healthcare Partners and
American Capital, Ltd. (NASDAQ: ACAS).
About AAIPharma Services Corp.
AAIPharma Services Corp. is a leading provider of contract
services that support all phases of drug development. The company's
wide array of capabilities includes analytical and formulation
development, material testing services, microbiology, clinical and
commercial contract manufacturing, pharmaceutical packaging and
stability services.
For more information on the company,
visit www.aaipharma.com.
About Cambridge Major Laboratories, Inc.
Cambridge Major Laboratories, Inc. (CML) is a leading global
chemistry outsourcing partner to the pharmaceutical and
biotechnology industries. The Company produces pharmaceutical
intermediates and Active Pharmaceutical Ingredients (API), from
early preclinical development to commercial manufacturing.
Operating from FDA-inspected facilities in the US and Europe, CML is organized along five key
Centers of Excellence, including: Process Chemistry, GMP
Manufacturing, Solid State Chemistry, Analytical Services, and
Quality/Regulatory Compliance. CML is a portfolio company of
American Capital, Ltd. (NASDAQ: ACAS).
For more information on the company, visit www.c-mlabs.com/.
Related Links:
AAIPharma Home Page:
http://aaipharma.com
Cambridge Major Laboratories Home Page
http://www.c-mlabs.com/
SOURCE AAIPharma Services Corp.; Cambridge Major Laboratories,
Inc.